refractory or relapsed
Relapsed vs. Refractory Multiple MyelomaVerywell Health
· Refractory is another word for resistant. Refractory myeloma is cancer that develops resistance to treatment or does not respond to it at all. There are two types of refractory myeloma
Get Price
Progress in the problem of relapsed or refractory acute
Purpose of review The majority of patients with acute myeloid leukemia (AML) die from disease recurrence and historically treatment options in both the relapsed and refractory settings of this disease have been limited. However new insights into the molecular characterization and biology of relapsed and refractory AML have led to novel therapeutics and improvement in outcomes in these settings.
Get PriceHodgkin Lymphoma Relapsed/RefractoryLRF
The term "relapsed" refers to disease that reappears or grows again after a period of remission. The term "refractory" is used to describe when the lymphoma does not respond to treatment (meaning that the cancer cells continue to grow) or when the response to treatment does not last very long.
Get Price
Relapsed or refractory diffuse large B cell lymphoma
· Diffuse large B cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma (NHL). For patients who are refractory to initial treatment or relapse after an initial response only a small percentage will experience prolonged disease-free survival with salvage chemoimmunotherapy alone 1 .
Get Price
FDA Approves New Treatment For Adults With Relapsed Or
· The safety and efficacy of Breyanzi were established in a multicenter clinical trial of more than 250 adults with refractory or relapsed large B-cell lymphoma. The complete remission rate after
Get Price
Gilteritinib or Chemotherapy for Relapsed or Refractory
· Patients with relapsed or refractory acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase 3 gene ( FLT3) infrequently have a
Get Price
Relapsed and Refractory Leukemia and Lymphoma Society
Patients who have not achieved complete remission after two cycles of induction chemotherapy are usually diagnosed as having "refractory AML." Relapsed AML Some patients reach remission and then have a return of leukemia cells in the marrow and a decrease in normal blood cells. This is called "relapsed leukemia."
Get PriceGilteritinib A Review in Relapsed or Refractory FLT3
· The efficacy of oral gilteritinib in treating relapsed or refractory FLT3-mutated AML was demonstrated in the randomized open-label multinational phase III ADMIRAL trial .Eligible patients were aged ≥ 18 years diagnosed with AML refractory to ≤ 2 cycles of conventional anthracycline-containing induction therapy (or ≥ 1 cycle of alternative standard induction therapy) or had
Get Price
Relapsed or refractory classical Hodgkin lymphoma which
· High-dose therapy and autologous haematopoietic stem-cell transplantation (HSCT) are the standard of care for relapsed or refractory classical Hodgkin lymphoma but older patients and those with prohibitive comorbidities or chemorefractory disease are not eligible. Furthermore roughly half of those undergoing autologous HSCT relapse and require further treatment.
Get Price
Pembrolizumab versus brentuximab vedotin in relapsed or
· Methods. In this randomised open-label phase 3 study patients aged 18 years or older with relapsed or refractory classical Hodgkin lymphoma with measurable disease and an Eastern Cooperative Oncology Group performance status of 0 or 1 who were ineligible for or had relapsed after autologous haematopoietic stem-cell transplantation (HSCT) were enrolled at 78 hospitals and cancer centres in
Get Price
U.S. FDA Approves Yescarta® for Relapsed or Refractory
· Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Get Price
Gilteritinib or Chemotherapy for Relapsed or Refractory
· Patients with relapsed or refractory acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase 3 gene ( FLT3) infrequently have a
Get Price
Gilteritinib A Review in Relapsed or Refractory FLT3
· The efficacy of oral gilteritinib in treating relapsed or refractory FLT3-mutated AML was demonstrated in the randomized open-label multinational phase III ADMIRAL trial .Eligible patients were aged ≥ 18 years diagnosed with AML refractory to ≤ 2 cycles of conventional anthracycline-containing induction therapy (or ≥ 1 cycle of alternative standard induction therapy) or had
Get Price
CD22 CAR T-cell therapy in refractory or relapsed B acute
· Pan J Yang JF Deng BP Zhao XJ Zhang X Lin YH et al. High efficacy and safety of low dose CD19 directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia
Get Price
Vemurafenib plus Rituximab in Refractory or Relapsed Hairy
· In clinical trials involving patients with refractory or relapsed HCL the targeting of BRAF V600E with the oral BRAF inhibitor vemurafenib led to a response in 91 of the patients 35 of the patients had a complete response. However the median relapse-free survival was only 9 months after treatment was stopped.
Get Price
Relapsed or Refractory Adult Acute Lymphoblastic Leukemia
Relapsed or Refractory Adult ALL Overview. Patients with progressive or relapsed adult ALL remain curable despite failing initial treatment. Patients failing treatment can be divided into two broad categories. Patients who fail to achieve an initial complete disappearance or remission of their cancer following a complete course of remission
Get Price
UpToDate
· Rowe JM Mazza JJ Hines JD et al. Mitoxantrone and etoposide in patients with relapsed and refractory acute nonlymphocytic leukemia. Haematol Blood Transfus 1990 33 326. Amadori S Arcese W Isacchi G et al. Mitoxantrone etoposide and intermediate-dose cytarabine an effective and tolerable regimen for the treatment of refractory acute
Get Price
Understanding Follicular Lymphoma Relapsed/Refractory
· Relapsed/Refractory TREATMENT OPTIONS Treatment for relapsed/refractory FL is based on a patient s age overall health symptoms prior therapy or therapies and the duration of remission from the last treatment they received. Chemotherapy radiation and monoclonal antibodies such as rituximab (Rituxan for intravenous infusion and
Get Price
What Is Relapsed vs. Refractory Myeloma The Myeloma
· The time to relapse is importanta shorter relapse period (less than six months) means a more aggressive disease. Refractory Myeloma. Dr. Damian Green MD of the Fred Hutchinson Cancer Center generally defines Refractory Myeloma as "disease that is progressing despite active treatment."
Get Price
U.S. FDA Approves Abecma for Relapsed or Refractory
· The FDA approval of Abecma is based on data from the pivotal Phase II KarMMa trial of 127 patients with relapsed or refractory multiple myeloma who had received at least three prior lines of therapy including an immunomodulatory agent a proteasome inhibitor and an anti-CD38 antibody.The efficacy evaluable population consists of 100 patients who received Abecma within the dose range of
Get PriceUnderstanding Follicular Lymphoma Relapsed/Refractory
· Relapsed/Refractory TREATMENT OPTIONS Treatment for relapsed/refractory FL is based on a patient s age overall health symptoms prior therapy or therapies and the duration of remission from the last treatment they received. Chemotherapy radiation and monoclonal antibodies such as rituximab (Rituxan for intravenous infusion and
Get PriceVenetoclax and Navitoclax in Combination with
Introduction. The prognosis for patients with relapsed/refractory acute lymphoblastic leukemia (ALL) remains poor particularly in those undergoing second or subsequent salvage therapy ().Complete remission (CR) rates as low as 44 and 18 have been reported with second salvage for pediatric and adult patients with relapsed/refractory ALL respectively ().
Get Price
Polatuzumab Vedotin in Relapsed or Refractory Diffuse
· PURPOSE Patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) fare poorly with limited treatment options. The antibody-drug conjugate polatuzumab vedotin targets CD79b a B-cell receptor component. METHODS Safety and efficacy of polatuzumab vedotin with bendamustine and obinutuzumab (pola-BG) was evaluated in a single-arm
Get Price
Alectinib for relapsed or refractory anaplastic lymphoma
· Patients with disease that is refractory to conventional chemotherapies have particularly poor prognoses. Brugieres et al 11 studied 36 pediatric patients treated weekly with vinblastine for relapsed or refractory ALCL this treatment was highly efficacious with a CR rate of 83 . However the 5-year EFS rate was 30 and the long-term
Get Price
Rituximab in relapsed or refractory hairy cell leukemia
· Abstract. The purpose of this study was to investigate the efficacy and safety of the monoclonal antibody rituximab in relapsed or refractory hairy cell leukemia (HCL). Fifteen patients with relapsed or primary refractory HCL after nucleoside analogs received rituximab 375 mg/m 2 weekly for a total of 8 planned doses.
Get Price
Relapsed or refractory classical Hodgkin lymphoma which
· High-dose therapy and autologous haematopoietic stem-cell transplantation (HSCT) are the standard of care for relapsed or refractory classical Hodgkin lymphoma but older patients and those with prohibitive comorbidities or chemorefractory disease are not eligible. Furthermore roughly half of those undergoing autologous HSCT relapse and require further treatment.
Get PricePolatuzumab Vedotin in Relapsed or Refractory Diffuse
· PURPOSE Patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) fare poorly with limited treatment options. The antibody-drug conjugate polatuzumab vedotin targets CD79b a B-cell receptor component. METHODS Safety and efficacy of polatuzumab vedotin with bendamustine and obinutuzumab (pola-BG) was evaluated in a single-arm
Get Price
Polatuzumab Vedotin in Relapsed or Refractory Diffuse
· PURPOSE Patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) fare poorly with limited treatment options. The antibody-drug conjugate polatuzumab vedotin targets CD79b a B-cell receptor component. METHODS Safety and efficacy of polatuzumab vedotin with bendamustine and obinutuzumab (pola-BG) was evaluated in a single-arm
Get Price
New Approaches to the Treatment of Relapsed or Refractory
· New Approaches to the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma. January 3 2021. Evolving Paradigms The Expanding Continuum of Care in Lymphoma In the United States the most common of the aggressive non-Hodgkin lymphomas (NHLs) is diffuse large B-cell lymphoma (DLBCL) which accounts for between 22 and 24 of newly
Get Price
